Literature DB >> 29892809

Current status of cancer immunotherapy for esophageal squamous cell carcinoma.

Koji Kono1, Kousaku Mimura2,3,4, Reo Yamada2, Daisuke Ujiie2, Suguru Hayase2, Takeshi Tada2, Hiroyuki Hanayama2, Aung Kyi Thar Min2, Masahiko Shibata2,3, Tomoyuki Momma2, Zenichirou Saze2, Shinji Ohki2.   

Abstract

BACKGROUND: Immunotherapy has become a promising treatment strategy for cancer. Immune checkpoint blockade with anti-CTLA4 mAb and anti-PD-1 mAb has demonstrated clear evidence of objective responses including improved overall survival and tumor shrinkage, driving renewed enthusiasm for cancer immunotherapy in multiple cancer types including esophageal squamous cell carcinoma (ESCC). There are several clinical trials using anti-PD1 mAb for ESCC in early phases and the results are currently promising. RESULTS AND
CONCLUSIONS: In this review, recent advances in cancer immunotherapy for ESCC are discussed with particular focus on immune checkpoint inhibitors and cancer vaccine.

Entities:  

Keywords:  Cancer vaccine; Esophageal cancer; Immune checkpoint inhibitors; Immunotherapy

Mesh：

Substances：

Year:  2017        PMID： 29892809     DOI： 10.1007/s10388-017-0596-2

Source DB:  PubMed          Journal:  Esophagus        ISSN： 1612-9059            Impact factor:   4.230


  50 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 2.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

Review 3.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

4.  Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Yoshiyuki Suzuki; Kousaku Mimura; Yuya Yoshimoto; Mitsuaki Watanabe; Yu Ohkubo; Shinichirou Izawa; Kazutoshi Murata; Hideki Fujii; Takashi Nakano; Koji Kono
Journal:  Cancer Res       Date:  2012-06-14       Impact factor: 12.701

5.  High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.

Authors:  Takuro Saito; Hisashi Wada; Makoto Yamasaki; Hiroshi Miyata; Hiroyoshi Nishikawa; Eiichi Sato; Shinichi Kageyama; Hiroshi Shiku; Masaki Mori; Yuichiro Doki
Journal:  Vaccine       Date:  2014-09-13       Impact factor: 3.641

6.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Authors:  Thomas Crosby; Christopher N Hurt; Stephen Falk; Simon Gollins; Somnath Mukherjee; John Staffurth; Ruby Ray; Nadim Bashir; John A Bridgewater; J Ian Geh; David Cunningham; Jane Blazeby; Rajarshi Roy; Tim Maughan; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316

10.  Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.

Authors:  Kaiyan Chen; Guoping Cheng; Fanrong Zhang; Nan Zhang; Dan Li; Jiaoyue Jin; Junzhou Wu; Lisha Ying; Weimin Mao; Dan Su
Journal:  Oncotarget       Date:  2016-05-24
View more
  7 in total

1.  Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report.

Authors:  Dongyang Yang; Fei Xu; Xiaorong Lai; Ying Li; Huibing Gao; Ying Xu; Rongrong Chen; Dong Ma
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 2.  The predictive value of microRNAs for pathological response after neoadjuvant treatment in esophageal squamous cell carcinoma: a systematic review.

Authors:  Dong Lin; Xiaosang Chen; Lijie Tan
Journal:  Ann Transl Med       Date:  2021-03

Review 3.  Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy.

Authors:  Xiu-Yong Liao; Chao-Yuan Liu; Jian-Feng He; Li-Shu Wang; Tao Zhang
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

4.  A Prognostic Signature Based on Immunogenomic Profiling Offers Guidance for Esophageal Squamous Cell Cancer Treatment.

Authors:  Jianyao Gao; Ting Tang; Baohui Zhang; Guang Li
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

5.  An Extracellular Matrix-Based Signature Associated With Immune Microenvironment Predicts the Prognosis and Therapeutic Responses of Patients With Oesophageal Squamous Cell Carcinoma.

Authors:  Hongpan Zhang; Qi Shi; Zhihao Yang; Kaige Wang; Zhiyu Zhang; Zheng Huang; Xiaobin Cui; Feng Li
Journal:  Front Mol Biosci       Date:  2021-03-18

6.  The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma.

Authors:  Seong Yong Park; Min Hee Hong; Hye Ryun Kim; Chang Geol Lee; Jae Ho Cho; Byoung Chul Cho; Dae Joon Kim
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

7.  Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening.

Authors:  Huizhen Ge; Lizeng Peng; Zhou Sun; Huanxiang Liu; Yulin Shen; Xiaojun Yao
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.